Insight

Wafik El-Deiry: Strategies for optimizing Spike as an immunogen in vaccines while minimizing suppression of p53 function

Photo of Wafik El-Deiry from brown.edu

Aug 19, 2024, 06:43

Wafik El-Deiry: Strategies for optimizing Spike as an immunogen in vaccines while minimizing suppression of p53 function

Wafik El-Deiry shared a post on LinkedIn:

“About our study in Oncotarget showing effects of Spike on p53, cancer is a complex multistep process involving multiple genetic and epigenetic alterations. Conclusions of a cancer link based on findings in cell culture would be premature without more studies.

As discussed in the interview we did not investigate a cancer endpoint, but found evidence of effects of spike on p53 function (effects on reporter activity, reduced upregulation of p53 transcriptional targets, altered sensitivity to chemo and a suggestion of altered DNA damaging sensing when Spike is over-expressed in human cancer cells that contain wild-type p53).

Our findings suggest strategies for optimizing Spike as an immunogen in vaccines while minimizing suppression of p53 function.

Our work suggests more studies of p53-dependent tumor suppression and repair pathways in the setting of COVID infection and vaccine development.

Study does not establish Covid-19 vaccine link to cancer.”

Read further.
Source: Wafik El-Deiry/LinkedIn

More posts by Wafik S. El-Deiry in OncoDaily.

Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals.

He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.